Details of the Drug Combinations

General Information of This Drug (ID: DMDHZR1)

Drug Name

GSK1016790A DMDHZR1

Synonyms

GSK1016790A; 942206-85-1; GSK 1016790A; GSK-1016790A; GSK101; (N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide; IVYQPSHHYIAUFO-VXKWHMMOSA-N; GTPL4205; SCHEMBL5007988; DTXSID30635248; CHEBI:140524; MolPort-044-560-329; EX-A1885; s8107; MFCD12912413; ZINC95571016; AKOS030527025; CS-5660; NCGC00250409-01

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GSK1016790A + Ruxolitinib	DCQSBA1	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[2]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4205).
2	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.